Logo image of GSD.CA

DEVONIAN HEALTH GROUP INC (GSD.CA) Stock Price, Forecast & Analysis

Canada - TSX Venture Exchange - TSX-V:GSD - CA2518348008 - Common Stock

11.5 CAD
0 (0%)
Last: 1/28/2026, 7:00:00 PM

GSD.CA Key Statistics, Chart & Performance

Key Statistics
Market Cap1.91B
Revenue(TTM)18.52M
Net Income(TTM)-6.97M
Shares165.94M
Float145.19M
52 Week High11.75
52 Week Low0.08
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.05
PEN/A
Fwd PEN/A
Earnings (Next)04-09
IPO2014-09-09
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
GSD.CA short term performance overview.The bars show the price performance of GSD.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 2K 4K 6K

GSD.CA long term performance overview.The bars show the price performance of GSD.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years 2K 4K 6K

The current stock price of GSD.CA is 11.5 CAD. In the past month the price increased by 5127.27%. In the past year, price increased by 7831.03%.

DEVONIAN HEALTH GROUP INC / GSD Daily stock chart

GSD.CA Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to GSD.CA. When comparing the yearly performance of all stocks, GSD.CA is one of the better performing stocks in the market, outperforming 99.97% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

GSD.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to GSD.CA. GSD.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GSD.CA Financial Highlights

Over the last trailing twelve months GSD.CA reported a non-GAAP Earnings per Share(EPS) of -0.05. The EPS decreased by -288.14% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -44.73%
ROE -72.55%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%-129.27%
Sales Q2Q%-82.81%
EPS 1Y (TTM)-288.14%
Revenue 1Y (TTM)-23.32%

GSD.CA Forecast & Estimates


Analysts
Analysts0
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

GSD.CA Ownership

Ownership
Inst OwnersN/A
Ins Owners12.1%
Short Float %N/A
Short RatioN/A

About GSD.CA

Company Profile

GSD logo image Devonian Health Group, Inc. is a pharmaceutical company, which engages in the development of botanical drugs. The company is headquartered in Montmagny, Quebec and currently employs 8 full-time employees. The company went IPO on 2014-09-09. The company specializes in the development of drugs for various autoimmune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. The company is developing prescription drugs for the treatment of inflammatory autoimmune diseases, including but not limited to, ulcerative colitis and atopic dermatitis. The company is also involved in the development of cosmeceutical products, leveraging the same proprietary approach employed with their pharmaceutical offerings. Its flagship product, Thykamine, is a pharmaceutical product issued from its SUPREX platform, for the prevention and treatment of health problems related to inflammation and oxidative stress, including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune diseases. Its cosmeceutical products include R-Spinasome and Purgenesis. Its subsidiary, Altius Healthcare Inc., sells prescription pharmaceutical products.

Company Info

DEVONIAN HEALTH GROUP INC

360 rue des Entrepreneurs

Montmagny QUEBEC G5V 4T1 CA

CEO: Andre P. Boulet

Employees: 7

GSD Company Website

GSD Investor Relations

Phone: 15142487509

DEVONIAN HEALTH GROUP INC / GSD.CA FAQ

What does GSD do?

Devonian Health Group, Inc. is a pharmaceutical company, which engages in the development of botanical drugs. The company is headquartered in Montmagny, Quebec and currently employs 8 full-time employees. The company went IPO on 2014-09-09. The company specializes in the development of drugs for various autoimmune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. The company is developing prescription drugs for the treatment of inflammatory autoimmune diseases, including but not limited to, ulcerative colitis and atopic dermatitis. The company is also involved in the development of cosmeceutical products, leveraging the same proprietary approach employed with their pharmaceutical offerings. Its flagship product, Thykamine, is a pharmaceutical product issued from its SUPREX platform, for the prevention and treatment of health problems related to inflammation and oxidative stress, including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune diseases. Its cosmeceutical products include R-Spinasome and Purgenesis. Its subsidiary, Altius Healthcare Inc., sells prescription pharmaceutical products.


Can you provide the latest stock price for DEVONIAN HEALTH GROUP INC?

The current stock price of GSD.CA is 11.5 CAD.


What is the dividend status of DEVONIAN HEALTH GROUP INC?

GSD.CA does not pay a dividend.


What is the ChartMill rating of DEVONIAN HEALTH GROUP INC stock?

GSD.CA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the GICS sector and industry of GSD stock?

DEVONIAN HEALTH GROUP INC (GSD.CA) operates in the Health Care sector and the Pharmaceuticals industry.


Can you provide the ownership details for GSD stock?

You can find the ownership structure of DEVONIAN HEALTH GROUP INC (GSD.CA) on the Ownership tab.